2026 DOJ and State AG Enforcement Trends for Health Care and Life Sciences

Gabe Scannapieco and Aaron Danzig, AGG Government Investigations partners, co-authored an article for Medical Economics discussing 2026 U.S. Department of Justice (“DOJ”) and state attorney general enforcement trends for the healthcare and life sciences industries.

Gabe and Aaron discussed how advanced analytics and multi-agency coordination are shortening investigative timelines and expanding parallel civil False Claims Act (“FCA”), criminal, administrative, and state litigation exposure from a single operational issue. They also highlighted how enterprise-level FCA theories are emphasizing systems, governance, and vendor relationships, with a sustained focus on managed care, prescription drugs, and medically unnecessary services.

“Taken together, the enforcement signals for 2026 are clear: regulators will continue to pursue familiar fraud and abuse priorities, but with better data and more coordination across federal and state agencies,” said Gabe and Aaron. “Investigations are increasingly likely to focus not only on claims accuracy, but also on the systems, incentives and vendor or platform relationships that shape coding, prescribing, billing and utilization decisions at scale.”

To read the full article and gain insights into 2026 DOJ and state AG enforcement trends, please click here.